Gilead Sciences delivered solid financial results for the fourth quarter of 2025, with revenue reaching $7.93 billion and exceeding Wall Street projections. The company's earnings per share of $1.86, while marginally below the year-ago $1.90, still surpassed consensus forecasts, demonstrating